Akademik Veri Yönetim Sistemi
Journal of Gastrointestinal Cancer, cilt.57, sa.1, 2026 (ESCI, Scopus)
Objective: Although bone metastases (BMs) are uncommon in colorectal cancer (CRC), they are a clinically significant problem. BMs are associated with a poor prognosis, and depending on the location, skeletal complications may occur. This study aims to evaluate the characteristics, treatment modalities, and prognostic factors affecting survival in patients with bone-metastatic CRC treated at a single institution. Materials and methods: This retrospective study included 59 patients diagnosed and followed up with bone-metastatic colorectal cancer at Marmara University Pendik Training and Research Hospital between January 2014 and December 2024. Demographic and clinical variables, including age, sex, tumor location, grade, mutation status, and metastatic spread, were examined. Bone Metastasis Progression-free survival (BM-PFS) and Bone Metastasis spesific overall survival (BM-OS) were assessed using the Kaplan-Meier method, and prognostic factors were assessed using Cox proportional hazard regression in univariate and multivariate models. Results: Median age of the patients was 59 years and 64.4% were male. The most common tumor involvements were sigmoid or descending colon (35.6%) and rectum (32.2%). BMs primarily involved the spinal vertebrae (49.1%) and pelvic bones (32.2%). Seventeen patients (28.8%) presented with de novo bone metastasis, and 44 patients (74.6%) had concurrent lymph node involvement. Antiresorptive therapy was administered to 15 patients (25.4%), and 49 (83.1%) received palliative radiotherapy. In survival analysis, age under 65 years was significantly associated with worse BM- PFS (HR = 2.44, 95% CI 1.30–4.57, p = 0.005) and BM-OS (HR = 1.85, 95% CI 1.01–3.40, p = 0.04). No significant correlation was observed with gender, tumor location, tumor grade or antiresorptive treatment use. Conclusion: BMs in patients with colorectal cancer show a heterogeneous distribution. In this study, younger patients (< 65 years) had poorer BM-PFS and BM-OS, suggesting potential underlying mutations and biological aggressiveness. Larger, molecular-based prospective studies are needed to confirm these findings and guide optimal treatment strategies.